Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • H-89: Selective PKA Inhibitor for cAMP Signaling Pathway ...

    2025-12-07

    H-89: Selective PKA Inhibitor for cAMP Signaling Pathway Modulation

    Executive Summary: H-89 is a selective inhibitor of cAMP-dependent protein kinase (PKA) with an IC50 of 48 nM, widely used to dissect cAMP signaling pathways in cellular research (APExBIO). The compound demonstrates minimal off-target effects against other kinases, supporting its use in signal transduction and metabolic modulation studies (You et al., 2024). H-89’s specificity enables precise evaluation of PKA function in cell proliferation, apoptosis, and disease modeling (summary). The stability and handling guidelines for H-89 are critical for reproducibility (product page). Recent research applies H-89 to unravel PKA-mediated regulation in bone formation and metabolic reprogramming (DOI).

    Biological Rationale

    cAMP-dependent protein kinase (PKA) is a master regulator of cellular signal transduction. It controls key processes including cell proliferation, apoptosis, metabolism, and differentiation (You et al., 2024). PKA is activated by intracellular cAMP, which is generated in response to extracellular stimuli. Modulation of PKA activity determines the downstream phosphorylation of various substrates, impacting gene expression and metabolic flux. In osteogenic cells, PKA is implicated in Wnt-induced aerobic glycolysis and O-GlcNAcylation, both essential for bone formation and fracture healing (DOI). Aberrant PKA signaling is associated with cancer progression, neurodegenerative diseases, and metabolic disorders (reference).

    Mechanism of Action of H-89

    H-89 (N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide) is a synthetic, cell-permeable molecule that selectively inhibits the catalytic subunit of PKA. Its inhibitory constant (IC50) for PKA is 48 nM, measured under buffer conditions at pH 7.4 and 25°C (APExBIO). H-89 competes with ATP for binding at the kinase catalytic site, blocking phosphorylation of downstream substrates. It exhibits >20-fold selectivity for PKA over PKG and Casein Kinase, minimizing off-target activity (You et al., 2024). By inhibiting PKA, H-89 prevents cAMP-mediated signal propagation, enabling dissection of PKA-specific pathways such as metabolic reprogramming during osteogenesis (contrast: this article updates mechanistic insights on metabolic modulation beyond classic PKA inhibition).

    Evidence & Benchmarks

    • H-89 inhibits PKA activity with an IC50 of 48 nM in in vitro kinase assays at 25°C, pH 7.4, ATP 10 µM (product page).
    • In Wnt-stimulated osteoblasts, pharmacologic PKA inhibition by H-89 blocks rapid O-GlcNAcylation and attenuates Wnt-induced bone formation (You et al., 2024).
    • H-89 shows negligible inhibition of PKG and Casein Kinase at concentrations up to 1 µM, confirmed by comparative kinase panel profiling (APExBIO).
    • In cell-based assays, H-89 at 10–20 µM suppresses cAMP-induced cell proliferation and promotes apoptosis in cancer and neurodegenerative models (benchmark summary).
    • H-89 is stable as a solid at −20°C for >1 year, but aqueous solutions lose potency if stored for >24 hours at room temperature (vendor data).
    • In metabolic studies, H-89 reveals PKA’s role in glucose metabolism and lactate production during Wnt-driven osteogenesis (You et al., 2024).

    Applications, Limits & Misconceptions

    H-89 is a preferred tool for dissecting cAMP signaling in cell proliferation assays, apoptosis research, cancer biology, neurodegenerative disease models, and metabolic studies. It enables precise modulation of PKA-dependent pathways, facilitating the identification of downstream effectors in complex signaling networks. Studies use H-89 to probe metabolic reprogramming, especially the shift toward aerobic glycolysis in bone formation (You et al., 2024).

    Compared with earlier summaries (see: prior review), this article emphasizes the integration of H-89 in metabolic pathway research and clarifies conditions for maximal selectivity.

    Common Pitfalls or Misconceptions

    • H-89 is not effective as a pan-kinase inhibitor; it does not block non-cAMP-related kinases at recommended concentrations (APExBIO).
    • Prolonged storage of H-89 in aqueous solution (>24 h at 4°C) significantly reduces inhibitory activity—use freshly prepared solutions (vendor protocol).
    • H-89 only inhibits PKA-driven pathways; parallel signaling (e.g., PKC, MAPK) is not affected unless used at supra-physiological doses, which may induce off-target effects (You et al., 2024).
    • Results from H-89 treatment must be interpreted within the context of cAMP pathway activation status; basal conditions may show minimal phenotypic change.
    • H-89 is not suitable for in vivo applications without pharmacokinetic and toxicity validation for the target organism (detailed Q&A).

    Workflow Integration & Parameters

    For optimal results, H-89 (SKU BA3584) should be dissolved in DMSO to a stock concentration of 10 mM and stored at −20°C (H-89 product page). Working solutions (0.5–50 µM) are freshly prepared in assay buffer and used within 2 hours. APExBIO ships the compound with blue ice to maintain stability. In cell-based experiments, typical exposure times are 30 minutes to 24 hours, with endpoint readouts for kinase activity, cell viability, or metabolic flux. For signal transduction studies, PKA activity is measured using phospho-substrate immunoblotting or kinase activity assays (this article provides benchmarks in cancer and neurodegeneration models, whereas this page details metabolic focus).

    H-89 integrates with cell proliferation assays, apoptosis detection kits, and metabolic flux analyzers. Researchers should include appropriate vehicle and positive controls. To avoid confounding effects, do not exceed 50 µM final concentration in cell culture. For comparability, record temperature, pH, and exposure duration for all experiments.

    Conclusion & Outlook

    H-89, as provided by APExBIO, remains a cornerstone reagent for selective inhibition of cAMP-dependent protein kinase in biochemical and cellular research. Its documented nanomolar potency, stability guidelines, and minimal off-target activity support its adoption in advanced workflows for cancer, bone, and neurodegenerative disease models. Recent findings highlight H-89’s value in elucidating metabolic reprogramming during osteogenic differentiation, extending its relevance beyond classical PKA signaling (You et al., 2024). Ongoing research will refine its applications in metabolic and signal transduction studies, enabling reproducible, mechanistic insights across biomedical disciplines.